title: Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post-liver transplant recipients.
authors.forename: Ashok
authors.initials: A
authors.lastname: Jain
authors.forename: Ravi
authors.initials: R
authors.lastname: Mohanka
authors.forename: Mark
authors.initials: M
authors.lastname: Orloff
authors.forename: Peter
authors.initials: P
authors.lastname: Abt
authors.forename: Charlotte
authors.initials: C
authors.lastname: Ryan
authors.forename: Adel
authors.initials: A
authors.lastname: Bozorgzadeh
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D016031:Liver Transplantation; D011183:Postoperative Complications; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir